|
Oseltamivir (Tamiflu®)
|
Influenza A and B
|
Treatment
|
Accelerates time to clinical symptom alleviation, reduces risk of lower respiratory tract complications, and admittance to hospital
|
[139], [140], [141], [142]
|
|
Chemoprophylaxis
|
Modest evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations
|
[141], [142]
|
|
Zanamivir (Relenza®)
|
Influenza A and B
|
Treatment
|
Decreases the risk of becoming symptomatic
|
[141], [143], [144], [145]
|
|
Chemoprophylaxis
|
|
Peramivir (Rapivab®)
|
Influenza A and B
|
Treatment
|
Reduces the time to alleviation of influenza symptoms
|
[146], [147]
|
|
Chemoprophylaxis
|
|
Baloxavir (Xofluza®)
|
Influenza A and B
|
Treatment
|
Effective in alleviating influenza symptoms and reducing the viral load 1 day after initiation
|
[148], [149], [150], [151], [57], [152]
|
|
Chemoprophylaxis
|
|
Laninamivir (Inavir®)
|
Influenza A and B
|
Treatment
|
Inhibited the NA activities, reduces duration of symptoms
|
[153], [154], [155], [56], [156], [55]
|
|
Chemoprophylaxis
|
